<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041417</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00030362</org_study_id>
    <secondary_id>1RC2HL101515-01</secondary_id>
    <nct_id>NCT01041417</nct_id>
  </id_info>
  <brief_title>Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease</brief_title>
  <acronym>GPAD-2</acronym>
  <official_title>Granulocyte-Macrophage Stimulating Factor (GM-CSF) and Mobilization of Progenitor Cells in Peripheral Arterial Disease: A Phase II Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripheral arterial disease is a common condition in older adults involving poor arterial
      circulation in the legs leading to leg pain and debility. The body's own circulating blood
      vessel stem cells may help to improve circulation. This study will test whether treatment
      with the drug granulocyte macrophage colony stimulating factor (GM-CSF) will improve symptoms
      and signs of peripheral arterial disease over placebo after four weeks of therapy. As well
      this study will examine whether improvements in blood vessel function can be observed.
      Finally, we will measure blood vessel function and stem cell levels in order to determine
      whether they can help to predict whether patients wither peripheral arterial disease will
      suffer further cardiovascular complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral artery disease (PAD) affects more than 8 million Americans. Although exercise,
      smoking cessation, anti-platelet therapy, cilostazol, statins and revascularization are used
      to treat PAD, men and women with PAD have significantly greater functional impairment and
      fasterfunctional decline than those without PAD. Stem and progenitor cell (PC) therapy that
      promotes neoangiogenesis is an emerging treatment modality in PAD. Progenitor cells,
      particularly those of endothelial origin, are involved in vascular repair and regeneration.
      They originate primarily but not exclusively from the bone marrow, differentiate into
      endothelial and other vascular cells, and contribute to neovascularization during tissue
      repair by direct and paracrine mechanisms. Endogenous, pharmacologically-stimulated, and
      exogenous PCs contribute to re-endothelialization and neovascularization. Granulocyte colony
      stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF)
      stimulate mobilization of hematopoietic and other PCs from the bone marrow.In the murine hind
      limb ischemia model, GM-CSF administered by injection or by plasmid transfer augments
      circulating levels of PCs, increases capillary density, and promotes arteriogenesis.GM-CSF
      also augments neo-endothelialization of denuded arteries, promotes proliferation,
      differentiation and survival of hematopoietic cells, monocytes and macrophages.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Peak Walking Time During Treadmill Exercise Tolerance Test From Baseline to 3 Months</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Exercise Tolerance Test (ETT) was conducted using the Gardner protocol. Participants exercised on a treadmill, starting at 2.0 mph. The intensity of exercise (speed) was increased in grade of 2% every 2 minutes. Participants were asked to exercise until symptom limitation and the time measured in seconds from the ETT was used for data analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Walking Time During Treadmill Exercise Tolerance Test From Baseline to 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Exercise Tolerance Test (ETT) was conducted using the Gardner protocol. Participants exercised on a treadmill, starting at 2.0 mph. The intensity of exercise (speed) was increased in grade of 2% every 2 minutes. Participants were asked to exercise until symptom limitation and the time measured in seconds from the ETT was used for data analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Claudication Onset Time (COT) From Baseline to 3 Months</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Claudication is pain, tired or weak feeling that occurs in the legs, usually during activity such as walking. The COT was measured as the time to onset of the participant's typical claudication as the maximum distance the patient could walk on the treadmill.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Claudication Onset Time (COT) From Baseline to 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Claudication is pain, tired or weak feeling that occurs in the legs, usually during activity such as walking. The COT was measured as the time to onset of the participant's typical claudication as the maximum distance the patient could walk on the treadmill.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Walking Distance Scores on Walking Impairment Questionnaire (WIQ) From Baseline to 3 Months</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with walking distance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Walking Distance Scores on Walking Impairment Questionnaire (WIQ) From Baseline to 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with walking distance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Walking Speed Score on Walking Impairment Questionnaire (WIQ) From Baseline to 3 Months</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with walking speed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Walking Speed Score on Walking Impairment Questionnaire (WIQ) From Baseline to 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with walking speed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stair Climbing Score on Walking Impairment Questionnaire (WIQ) From Baseline to 3 Months</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with stair climbing elements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stair Climbing Score on Walking Impairment Questionnaire (WIQ) From Baseline to 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with stair climbing elements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score on Physical Composite Score (PCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 3 Months</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>The SF-36 is a standard quality of life instrument. The PCS represents the the physical burden on quality of life and is a summary of questions related to physical impact of a disease or condition (physical function, role physical, bodily pain, and general health). PCS is a summary measure derived from 8 scale score and the score ranges from 0-100; higher scores indicate better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score on Physical Composite Score (PCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>The SF-36 is a standard quality of life instrument. The PCS represents the the physical burden on quality of life and is a summary of questions related to physical impact of a disease or condition (physical function, role physical, bodily pain, and general health). PCS is a summary measure derived from 8 scale score and the score ranges from 0-100; higher scores indicate better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score on Mental Composite Score (MCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 3 Months</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>The SF-36 is a standard quality of life instrument. The MCS represents the the mental burden on quality of life and is a summary of questions related to mental impact of a disease or condition (mental function, role emotional, vitality, and mental health). MCS is a summary measure derived from 8 scale score and the score ranges from 0-100; higher scores indicate better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score on Mental Composite Score (MCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>The SF-36 is a standard quality of life instrument. The MCS represents the the mental burden on quality of life and is a summary of questions related to mental impact of a disease or condition (mental function, role emotional, vitality, and mental health). MCS is a summary measure derived from 8 scale score and the score ranges from 0-100; higher scores indicate better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score on Physical Functioning Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 3 Months</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>The SF-36 is a standard quality of life instrument. The physical functioning represents limitations in physical activities because of health problems. Physical functioning is a summary measure derived from 8 scale scores and the score ranges from 0-100; higher scores indicate better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score on Physical Functioning Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 6 Months</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>The SF-36 is a standard quality of life instrument. The physical functioning represents limitations in physical activities because of health problems. Physical functioning is a summary measure derived from 8 scale scores and the score ranges from 0-100; higher scores indicate better performance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive GM-CSF 500Î¼g (Sargramostim (Leukine), Sanofi Aventis) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a saline injection (placebo) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte-Macrophage Stimulating Factor (GM-CSF)</intervention_name>
    <description>500 micrograms of GM-CSF</description>
    <arm_group_label>GM-CSF</arm_group_label>
    <other_name>GM-CSF, Leukine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  160 males or post-menopausal females between 21 and 80 years of age. Female subjects
             must be (a) post-menopausal, (b) surgically sterile or (c) use adequate birth control
             and have a negative pregnancy test within 3 days prior to administration of study drug
             and should not be breastfeeding.

          -  Documented PAD (By Ankle-Brachial Indices or Angiographically)

          -  Clinically stable (at least 2 months) history of intermittent claudication with no
             change in symptom severity in the 2 months prior to screening.

          -  On stable statin therapy for previous 3 months.

          -  Peak Walking Time (PWT) between 1 and 12 minutes on a standardized Gardner treadmill
             protocol.

          -  A Doppler-derived ankle-brachial index (ABI) of &lt; 0.85 in the symptomatic limb after
             10 minutes of rest at screening. For subjects with an ABI of &gt;1.3 (non-compressible
             arteries) a Toe-Brachial Index (TBI) of &lt; 0.70 must be obtained for subject
             qualification, or if ABI is &gt; 0.85 to 1.0 , and a reduction of 20% in ABI measured
             within 1 minute of treadmill testing.

          -  On appropriate and stable medical therapy for atherosclerosis for at least 2 months.

          -  Able to give informed consent.

          -  Diabetics with a dilated eye exam excluding proliferative retinopathy in the previous
             12 months.

        Exclusion Criteria:

          -  Recent or current active infections (treated with antibiotics).

          -  Recent (3 months) change in statin therapy

          -  Critical limb ischemia either chronic (category 3 and 4 of SVS classification) or
             acute ischemia manifested by rest pain, ulceration, or gangrene.

          -  Lower extremity vascular surgery, angioplasty or lumbar sympathectomy within 3 months
             of enrollment.

          -  Participation in a structured exercise treatment protocol within 3 months of
             enrollment.

          -  Prior myeloid cancer.

          -  Unstable angina, myocardial infarction, TIA, stroke or revascularization in the
             preceding 4 months.

          -  Severe heart failure (Class III or IV), heart muscle disease or atrial fibrillation.

          -  Limitation on exercise for symptoms other than intermittent claudication such as
             arthritis or dyspnea.

          -  Uncontrolled diabetes mellitus (defined as HbA1c &gt; 10.0).

          -  Chronic renal disease (creatinine of &gt;2.5 mg/dl) or hepatic disease (&gt; 3 X elevations
             in AST and ALT).

          -  Ophthalmologic conditions associated with a neo-vascular response.

          -  Alcohol or drug abuse, or any other disease process that, in the opinion of the PI,
             will interfere with the ability of the patient to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arshed Quyyumi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2009</study_first_submitted>
  <study_first_submitted_qc>December 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2009</study_first_posted>
  <results_first_submitted>May 15, 2014</results_first_submitted>
  <results_first_submitted_qc>December 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2014</results_first_posted>
  <last_update_submitted>December 12, 2014</last_update_submitted>
  <last_update_submitted_qc>December 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Arshed A. Quyyumi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>claudication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between January 2010 and July 2012, 322 individuals with peripheral artery disease were assessed for eligibility. 159 subjects were enrolled into the study from Emory Healthcare, Veterans Affairs hospitals in Atlanta, and Medical College of Georgia.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>GM-CSF</title>
          <description>Granulocyte-Macrophage Colony Stimulating Factor injection - three times for four weeks
500 microgram dose of GM-CSF</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Saline injection - three times for four weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GM-CSF</title>
          <description>Granulocyte-Macrophage Colony Stimulating Factor injection - three times for four weeks
500 microgram dose of GM-CSF</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Saline injection - three times for four weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="159"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" spread="7.9"/>
                    <measurement group_id="B2" value="63.6" spread="7.9"/>
                    <measurement group_id="B3" value="63.9" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Peak Walking Time During Treadmill Exercise Tolerance Test From Baseline to 3 Months</title>
        <description>Exercise Tolerance Test (ETT) was conducted using the Gardner protocol. Participants exercised on a treadmill, starting at 2.0 mph. The intensity of exercise (speed) was increased in grade of 2% every 2 minutes. Participants were asked to exercise until symptom limitation and the time measured in seconds from the ETT was used for data analysis.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor injection - three times for four weeks
500 microgram dose of GM-CSF</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline injection - three times for four weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Walking Time During Treadmill Exercise Tolerance Test From Baseline to 3 Months</title>
          <description>Exercise Tolerance Test (ETT) was conducted using the Gardner protocol. Participants exercised on a treadmill, starting at 2.0 mph. The intensity of exercise (speed) was increased in grade of 2% every 2 minutes. Participants were asked to exercise until symptom limitation and the time measured in seconds from the ETT was used for data analysis.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" spread="248" lower_limit="67" upper_limit="151"/>
                    <measurement group_id="O2" value="56" spread="182" lower_limit="14" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peak Walking Time During Treadmill Exercise Tolerance Test From Baseline to 6 Months</title>
        <description>Exercise Tolerance Test (ETT) was conducted using the Gardner protocol. Participants exercised on a treadmill, starting at 2.0 mph. The intensity of exercise (speed) was increased in grade of 2% every 2 minutes. Participants were asked to exercise until symptom limitation and the time measured in seconds from the ETT was used for data analysis.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor injection - three times for four weeks
500 microgram dose of GM-CSF</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline injection - three times for four weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Walking Time During Treadmill Exercise Tolerance Test From Baseline to 6 Months</title>
          <description>Exercise Tolerance Test (ETT) was conducted using the Gardner protocol. Participants exercised on a treadmill, starting at 2.0 mph. The intensity of exercise (speed) was increased in grade of 2% every 2 minutes. Participants were asked to exercise until symptom limitation and the time measured in seconds from the ETT was used for data analysis.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" lower_limit="71" upper_limit="153"/>
                    <measurement group_id="O2" value="77" lower_limit="36" upper_limit="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Claudication Onset Time (COT) From Baseline to 3 Months</title>
        <description>Claudication is pain, tired or weak feeling that occurs in the legs, usually during activity such as walking. The COT was measured as the time to onset of the participant's typical claudication as the maximum distance the patient could walk on the treadmill.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor injection - three times for four weeks
500 microgram dose of GM-CSF</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline injection - three times for four weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Claudication Onset Time (COT) From Baseline to 3 Months</title>
          <description>Claudication is pain, tired or weak feeling that occurs in the legs, usually during activity such as walking. The COT was measured as the time to onset of the participant's typical claudication as the maximum distance the patient could walk on the treadmill.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="52" upper_limit="111"/>
                    <measurement group_id="O2" value="61" lower_limit="32" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Claudication Onset Time (COT) From Baseline to 6 Months</title>
        <description>Claudication is pain, tired or weak feeling that occurs in the legs, usually during activity such as walking. The COT was measured as the time to onset of the participant's typical claudication as the maximum distance the patient could walk on the treadmill.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor injection - three times for four weeks
500 microgram dose of GM-CSF</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline injection - three times for four weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Claudication Onset Time (COT) From Baseline to 6 Months</title>
          <description>Claudication is pain, tired or weak feeling that occurs in the legs, usually during activity such as walking. The COT was measured as the time to onset of the participant's typical claudication as the maximum distance the patient could walk on the treadmill.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="64" upper_limit="122"/>
                    <measurement group_id="O2" value="61" lower_limit="33" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Walking Distance Scores on Walking Impairment Questionnaire (WIQ) From Baseline to 3 Months</title>
        <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with walking distance.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor: 80 subjects were randomized to receive GM-CSF Monday, Wednesday and Friday for 4 weeks of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 79 subjects were randomized to receive placebo on Monday, Wednesday and Friday for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Walking Distance Scores on Walking Impairment Questionnaire (WIQ) From Baseline to 3 Months</title>
          <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with walking distance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="27.6" lower_limit="6.4" upper_limit="18.7"/>
                    <measurement group_id="O2" value="4.8" spread="24.8" lower_limit="-0.2" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Walking Distance Scores on Walking Impairment Questionnaire (WIQ) From Baseline to 6 Months</title>
        <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with walking distance.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor injection - three times for four weeks
500 microgram dose of GM-CSF</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline injection - three times for four weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Walking Distance Scores on Walking Impairment Questionnaire (WIQ) From Baseline to 6 Months</title>
          <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with walking distance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="2.1" upper_limit="14.0"/>
                    <measurement group_id="O2" value="3.7" lower_limit="-0.9" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Walking Speed Score on Walking Impairment Questionnaire (WIQ) From Baseline to 3 Months</title>
        <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with walking speed.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor: 80 subjects were randomized to receive GM-CSF Monday, Wednesday and Friday for 4 weeks of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 79 subjects were randomized to receive placebo on Monday, Wednesday and Friday for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Walking Speed Score on Walking Impairment Questionnaire (WIQ) From Baseline to 3 Months</title>
          <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with walking speed.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="4.2" upper_limit="14.0"/>
                    <measurement group_id="O2" value="7.5" lower_limit="2.1" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Walking Speed Score on Walking Impairment Questionnaire (WIQ) From Baseline to 6 Months</title>
        <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with walking speed.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor: 80 subjects were randomized to receive GM-CSF Monday, Wednesday and Friday for 4 weeks of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 79 subjects were randomized to receive placebo on Monday, Wednesday and Friday for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Walking Speed Score on Walking Impairment Questionnaire (WIQ) From Baseline to 6 Months</title>
          <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with walking speed.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="4.6" upper_limit="15.3"/>
                    <measurement group_id="O2" value="8.5" lower_limit="3.8" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Stair Climbing Score on Walking Impairment Questionnaire (WIQ) From Baseline to 3 Months</title>
        <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with stair climbing elements.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor: 80 subjects were randomized to receive GM-CSF Monday, Wednesday and Friday for 4 weeks of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 79 subjects were randomized to receive placebo on Monday, Wednesday and Friday for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Stair Climbing Score on Walking Impairment Questionnaire (WIQ) From Baseline to 3 Months</title>
          <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with stair climbing elements.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="3.0" upper_limit="13.9"/>
                    <measurement group_id="O2" value="4.2" lower_limit="-2.2" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Stair Climbing Score on Walking Impairment Questionnaire (WIQ) From Baseline to 6 Months</title>
        <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with stair climbing elements.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor: 80 subjects were randomized to receive GM-CSF Monday, Wednesday and Friday for 4 weeks of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 79 subjects were randomized to receive placebo on Monday, Wednesday and Friday for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Stair Climbing Score on Walking Impairment Questionnaire (WIQ) From Baseline to 6 Months</title>
          <description>The WIQ quantifies walking difficulty on a 100-point scale, in which 0 indicates extreme difficulty and 100 indicates no difficulty with stair climbing elements.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="4.9" upper_limit="15.9"/>
                    <measurement group_id="O2" value="6.6" lower_limit="1.2" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Score on Physical Composite Score (PCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 3 Months</title>
        <description>The SF-36 is a standard quality of life instrument. The PCS represents the the physical burden on quality of life and is a summary of questions related to physical impact of a disease or condition (physical function, role physical, bodily pain, and general health). PCS is a summary measure derived from 8 scale score and the score ranges from 0-100; higher scores indicate better performance.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor injection - three times for four weeks
500 microgram dose of GM-CSF</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline injection - three times for four weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score on Physical Composite Score (PCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 3 Months</title>
          <description>The SF-36 is a standard quality of life instrument. The PCS represents the the physical burden on quality of life and is a summary of questions related to physical impact of a disease or condition (physical function, role physical, bodily pain, and general health). PCS is a summary measure derived from 8 scale score and the score ranges from 0-100; higher scores indicate better performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="2.4" upper_limit="5.8"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.5" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Score on Physical Composite Score (PCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 6 Months</title>
        <description>The SF-36 is a standard quality of life instrument. The PCS represents the the physical burden on quality of life and is a summary of questions related to physical impact of a disease or condition (physical function, role physical, bodily pain, and general health). PCS is a summary measure derived from 8 scale score and the score ranges from 0-100; higher scores indicate better performance.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor injection - three times for four weeks
500 microgram dose of GM-CSF</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline injection - three times for four weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score on Physical Composite Score (PCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 6 Months</title>
          <description>The SF-36 is a standard quality of life instrument. The PCS represents the the physical burden on quality of life and is a summary of questions related to physical impact of a disease or condition (physical function, role physical, bodily pain, and general health). PCS is a summary measure derived from 8 scale score and the score ranges from 0-100; higher scores indicate better performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="3.3" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.1" lower_limit="1.5" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Score on Mental Composite Score (MCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 3 Months</title>
        <description>The SF-36 is a standard quality of life instrument. The MCS represents the the mental burden on quality of life and is a summary of questions related to mental impact of a disease or condition (mental function, role emotional, vitality, and mental health). MCS is a summary measure derived from 8 scale score and the score ranges from 0-100; higher scores indicate better performance.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor injection - three times for four weeks
500 microgram dose of GM-CSF</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline injection - three times for four weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score on Mental Composite Score (MCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 3 Months</title>
          <description>The SF-36 is a standard quality of life instrument. The MCS represents the the mental burden on quality of life and is a summary of questions related to mental impact of a disease or condition (mental function, role emotional, vitality, and mental health). MCS is a summary measure derived from 8 scale score and the score ranges from 0-100; higher scores indicate better performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="-1.5" upper_limit="2.9"/>
                    <measurement group_id="O2" value="2.4" lower_limit="-0.2" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Score on Mental Composite Score (MCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 6 Months</title>
        <description>The SF-36 is a standard quality of life instrument. The MCS represents the the mental burden on quality of life and is a summary of questions related to mental impact of a disease or condition (mental function, role emotional, vitality, and mental health). MCS is a summary measure derived from 8 scale score and the score ranges from 0-100; higher scores indicate better performance.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor injection - three times for four weeks
500 microgram dose of GM-CSF</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline injection - three times for four weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score on Mental Composite Score (MCS) Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 6 Months</title>
          <description>The SF-36 is a standard quality of life instrument. The MCS represents the the mental burden on quality of life and is a summary of questions related to mental impact of a disease or condition (mental function, role emotional, vitality, and mental health). MCS is a summary measure derived from 8 scale score and the score ranges from 0-100; higher scores indicate better performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-2.4" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.1" lower_limit="-1.0" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Score on Physical Functioning Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 3 Months</title>
        <description>The SF-36 is a standard quality of life instrument. The physical functioning represents limitations in physical activities because of health problems. Physical functioning is a summary measure derived from 8 scale scores and the score ranges from 0-100; higher scores indicate better performance.</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor injection - three times for four weeks
500 microgram dose of GM-CSF</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline injection - three times for four weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score on Physical Functioning Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 3 Months</title>
          <description>The SF-36 is a standard quality of life instrument. The physical functioning represents limitations in physical activities because of health problems. Physical functioning is a summary measure derived from 8 scale scores and the score ranges from 0-100; higher scores indicate better performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="6.7" upper_limit="16.1"/>
                    <measurement group_id="O2" value="4.8" lower_limit="-0.1" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Score on Physical Functioning Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 6 Months</title>
        <description>The SF-36 is a standard quality of life instrument. The physical functioning represents limitations in physical activities because of health problems. Physical functioning is a summary measure derived from 8 scale scores and the score ranges from 0-100; higher scores indicate better performance.</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GM-CSF</title>
            <description>Granulocyte-Macrophage Colony Stimulating Factor injection - three times for four weeks
500 microgram dose of GM-CSF</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline injection - three times for four weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score on Physical Functioning Subscale of the Short Form 36 Health Survey (SF-36) From Baseline to 6 Months</title>
          <description>The SF-36 is a standard quality of life instrument. The physical functioning represents limitations in physical activities because of health problems. Physical functioning is a summary measure derived from 8 scale scores and the score ranges from 0-100; higher scores indicate better performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="9.7" upper_limit="18.9"/>
                    <measurement group_id="O2" value="8.1" lower_limit="3.7" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected at weeks 1, 2, 3, 4, 8 and 3 month follow-up and 6 month follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GM-CSF</title>
          <description>Granulocyte-Macrophage Colony Stimulating Factor injection - Monday, Wednesday and Friday for 4 weeks of therapy.
500 microgram dose of GM-CSF</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Saline injection - Monday, Wednesday and Friday for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Small Bowel Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain, non-cardiac</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Trauma</sub_title>
                <description>Admission for trauma</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Esophageal Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Elective Procedure</sub_title>
                <description>Admission for elective procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Critical Limb Ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty breathing</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal side effects</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="80"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="80"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="80"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint/back/muscle pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="80"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="80"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study population were subjects with claudication who underwent angiography. Study design could not show therapeutic benefit of GM-CSF therapy with dose and duration changes. And study design encouraged all subjects to walk to claudication daily.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Arshed Quyyumi</name_or_title>
      <organization>Emory University School of Medicine</organization>
      <phone>4047273655</phone>
      <email>aquyyum@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

